Effects of doxazosin in men with benign prostatic hyperplasia: Urodynamic assessment

International Urology and Nephrology

Volumn 31, Issue 4, 1999, Pages 471-479

  Ozbey I ^a   Aksoy, Y ^a   Polat, O ^a   Bicgi O ^a   Demirel, A ^a   Okyar, G ^a  

^a ATATURK UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN;

ADULT; AGED; ARTICLE; BLADDER CAPACITY; BLADDER NECK STENOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; URODYNAMICS;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; DOXAZOSIN; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; SAFETY; TREATMENT OUTCOME; URODYNAMICS;

EID: 0033403065     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007111211130     Document Type: Article

References (20)

1. Boyle, P.: Epidemiology of benign prostatic hyperplasia: Risk factors and concomitance with hypertension. Br. J. Clin. Pract., 74 (Suppl.), 18 (1994).
2. Mc Connel, J. D., Barry, M. J., Bruskewitz, R. C., Bueschen, A. J., Denton, S. E., Haltgrewe, H. L., Lange, J. L., Mc Clennon, B. L., Mebust, W. K., Reilly, N. J., Roberts, R. G., Sacks, S. A., Wasson, J. H.: Benign prostatic hyperplasia: Diagnosis and treatment. Quick reference guide for clinicians. AHCPR Publ No 94-0583. Rockville, Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, February 1994.
3. The 3rd International Consultation on BPH: Recommendations of the International Consensus Committee. In: Cockett, A. T. K., Khoury, S., Aso, Y., Chatelain, C., Denis, L., Griffiths, K., Murphy, G. (eds): Proceedings of the 3rd International Consultation on BPH, Monaco, June 26-28, 1995. Channel Islands, Scientific Communication International. 1996, pp. 625-640.
4. Jimenez, C. J. F.: The role of alpha-adrenergic blockers in the treatment of prostatic hypertrophy. Drugs Today, 29, 343 (1993).
5. Barry, M. J., Mulley, A. G., Fowler, F. J., Wennberg, J. W.: Watchful waiting versus immediate transurethral resection for symptomatic proslatism: The importance of patients' references. JAMA, 259, 3010 (1988).
6. Fowler, F. J., Jr., Wennberg, J. E., Timothy, R. P., Barry, M. J., Mulley, A. G., Jr., Hanley, D.: Symptom status and quality of life following prostatectomy. JAMA, 259, 3018 (1988).
7. Ross, N. P., Wennberg, J. E., Malenka, D. J., Fisher, E. S., Mc Pherson, K., Andersen, T. F., Cohen, M. M., Ramsey, E.: Mortality and reoperation after open and transurethral resection of prostate for benign prostatic hyperplasia. N. Engl. J. Med., 320, 1120 (1989).
8. Kirby, R. S., Coppinfer, S. W. L., Corcoran, M. O., Chapple, C. R., Flannagan, M., Nilroy, E. J. G.: Prazosin in the treatment of prostatic obstruction: A placebo-controlled study. Br. J. Urol., 60, 136 (1987).
9. Chapple, C. R., Christmas, T. J., Milroy, E. J.: A twelve-week, placebo controlled study of prazosin in the treatment of prostatic obstruction. Urol. Int., 45 (Suppl 1), 47 (1990).
10. Fawzy, A., Braun, K., Lewis, G. P., Gaffrey, M., Ice, K., Dias, N., for the multicenter study group: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study. J. Urol., 154, 105 (1995).
11. Caine, M., Pfan, A., Pelberg, S.: The use of alpha-adrenergic blockers in benign prostatic obstruction. Br. J. Urol., 47, 255 (1976).
12. Lepor, H.: Medical therapy for BPH. Urology, 42, 483 (1993).
13. Perlberg, S., Caine, M.: Adrenergic response of bladder muscle in prostatic obstruction: Its relation to detrusor instability. Urology, 20, 524 (1982).
14. McConnel, J. D.: Epidemiology, etiology, pathophysiology and diagnosis of benign prostatic hyperplasia. In: Walsh, P. C., Retik, A. B., Vaughan, E. D., Wein, A. J. (eds): Campbell's Urology. Seventh edition, W. B. Saunders Co., Philadelphia 1998, p. 1429.
15. Abrams, P.: Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction: Results from three double-blind placebo controlled studies. European Urology, 32/1, 39 (1997).
16. Hedlung, A., Andersson, K. E., Ek, A.: Effects of prazosin in patients with benign prostatic obstruction. J. Urol., 130, 275 (1983).
17. Christensen. M. M., Holme, J. B., Rasmussen, P. C.: Doxazosin treatment in patients with prostatic obstruction, a double-blind, placebo controlled study. Scand. J. Urol Nephrol., 27 (1), 39 (1993).
18. Holme, J. B., Christensen, M. M., Rasmussen, P. C.: 29 week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia, a double-blind, placebo controlled study. Scand. J. Urol., Nephrol., 28, 77 (1994).
19. Janknegt, R. A., Chapple, C. R.: Efficacy and safety of the alpha 1-blocker doxazosin in treatment of benign prostatic hyperplasia. Analysis of 5 studies. Eur. Urol., 24 (3), 319 (1993).
20. Gillenwater, J. Y., Conn, R. L., Chrysant, S. G., Roy, J., Gaffney, M., Ice, K., Dias, N., for the multicenter study group: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo controlled, dose-response multicenter study. J. Urol., 154, 110 (1995).